Comerica Bank Coherus Bio Sciences, Inc. Transaction History

Comerica Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 21, 2023	BUY	$3.74 - $5.45 $213 - $310	57 New	57 $0
Q4 2022 Jan 26, 2023	SELL	$5.69 - $10.07 $60,928 - $107,829	-10,708 Reduced 22.03%	37,892 $0
Q3 2022 Oct 28, 2022	SELL	$7.17 - $13.87 $42,876 - $82,942	-5,980 Reduced 10.96%	48,600 $407,000
Q2 2022 Aug 02, 2022	BUY	$5.86 - $13.23 $6,592 - $14,883	1,125 Added 2.1%	54,580 $416,000
Q1 2022 Apr 27, 2022	SELL	$10.92 - $16.41 $18,978 - $28,520	-1,738 Reduced 3.15%	53,455 $690,000
Q4 2021 Feb 18, 2022	SELL	$15.81 - $18.99 $37,706 - $45,291	-2,385 Reduced 4.14%	55,193 $880,000
Q3 2021 Nov 22, 2021	SELL	$12.68 - $17.79 $60,737 - $85,214	-4,790 Reduced 7.68%	57,578 $925,000
Q2 2021 Aug 26, 2021	SELL	$12.95 - $15.41 $27,246 - $32,422	-2,104 Reduced 3.26%	62,368 $862,000
Q1 2021 Apr 28, 2021	SELL	$14.42 - $21.39 $34,853 - $51,699	-2,417 Reduced 3.61%	64,472 $941,000
Q4 2020 Jan 28, 2021	BUY	$16.56 - $18.94 $20,468 - $23,409	1,236 Added 1.88%	66,889 $1.16 Million
Q3 2020 Oct 30, 2020	BUY	$17.41 - $19.89 $23,816 - $27,209	1,368 Added 2.13%	65,653 $1.2 Million
Q2 2020 Jul 31, 2020	BUY	$14.43 - $19.16 $927,632 - $1.23 Million	64,285 New	64,285 $1.15 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $115M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

Stay updated on Comerica Bank with notifications on news.